Logo image of SRZN

SURROZEN INC (SRZN) Stock Fundamental Analysis

NASDAQ:SRZN - Nasdaq - US86889P2083 - Common Stock - Currency: USD

11.2  -0.35 (-3.03%)

Fundamental Rating

2

Taking everything into account, SRZN scores 2 out of 10 in our fundamental rating. SRZN was compared to 571 industry peers in the Biotechnology industry. SRZN has a great financial health rating, but its profitability evaluates not so good. SRZN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SRZN had negative earnings in the past year.
SRZN had a negative operating cash flow in the past year.
In the past 5 years SRZN always reported negative net income.
SRZN had a negative operating cash flow in each of the past 5 years.
SRZN Yearly Net Income VS EBIT VS OCF VS FCFSRZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

SRZN has a Return On Assets of -92.58%. This is in the lower half of the industry: SRZN underperforms 73.00% of its industry peers.
SRZN's Return On Equity of -784.15% is on the low side compared to the rest of the industry. SRZN is outperformed by 82.77% of its industry peers.
Industry RankSector Rank
ROA -92.58%
ROE -784.15%
ROIC N/A
ROA(3y)-57.84%
ROA(5y)-56.7%
ROE(3y)-70.22%
ROE(5y)-72.54%
ROIC(3y)N/A
ROIC(5y)N/A
SRZN Yearly ROA, ROE, ROICSRZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

SRZN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRZN Yearly Profit, Operating, Gross MarginsSRZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

7

2. Health

2.1 Basic Checks

SRZN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRZN has been reduced compared to 1 year ago.
There is no outstanding debt for SRZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRZN Yearly Shares OutstandingSRZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
SRZN Yearly Total Debt VS Total AssetsSRZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SRZN has an Altman-Z score of -7.61. This is a bad value and indicates that SRZN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.61, SRZN is not doing good in the industry: 69.45% of the companies in the same industry are doing better.
There is no outstanding debt for SRZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.61
ROIC/WACCN/A
WACC9.44%
SRZN Yearly LT Debt VS Equity VS FCFSRZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

SRZN has a Current Ratio of 7.40. This indicates that SRZN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.40, SRZN is in the better half of the industry, outperforming 69.80% of the companies in the same industry.
A Quick Ratio of 7.40 indicates that SRZN has no problem at all paying its short term obligations.
SRZN has a better Quick ratio (7.40) than 69.80% of its industry peers.
Industry RankSector Rank
Current Ratio 7.4
Quick Ratio 7.4
SRZN Yearly Current Assets VS Current LiabilitesSRZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.91% over the past year.
Looking at the last year, SRZN shows a very negative growth in Revenue. The Revenue has decreased by -20.00% in the last year.
EPS 1Y (TTM)38.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.37%
Revenue 1Y (TTM)-20%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SRZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.28% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.81%
EPS Next 2Y31.36%
EPS Next 3Y19.28%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRZN Yearly Revenue VS EstimatesSRZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2M 4M 6M 8M 10M
SRZN Yearly EPS VS EstimatesSRZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SRZN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SRZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRZN Price Earnings VS Forward Price EarningsSRZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRZN Per share dataSRZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

SRZN's earnings are expected to grow with 19.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.36%
EPS Next 3Y19.28%

More info and screens

0

5. Dividend

5.1 Amount

SRZN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURROZEN INC

NASDAQ:SRZN (2/21/2025, 8:00:00 PM)

11.2

-0.35 (-3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)N/A N/A
Inst Owners78.43%
Inst Owner Change12.96%
Ins Owners1.29%
Ins Owner Change-0.52%
Market Cap36.40M
Analysts80
Price Target32.64 (191.43%)
Short Float %4.36%
Short Ratio3.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.19%
Min EPS beat(2)45.89%
Max EPS beat(2)82.5%
EPS beat(4)3
Avg EPS beat(4)21.61%
Min EPS beat(4)-44.12%
Max EPS beat(4)82.5%
EPS beat(8)5
Avg EPS beat(8)20.66%
EPS beat(12)8
Avg EPS beat(12)17.81%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.6%
EPS NQ rev (3m)4.63%
EPS NY rev (1m)0.5%
EPS NY rev (3m)12.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.64
P/FCF N/A
P/OCF N/A
P/B 6.42
P/tB 6.42
EV/EBITDA N/A
EPS(TTM)-10.63
EYN/A
EPS(NY)-5.86
Fwd EYN/A
FCF(TTM)-8.75
FCFYN/A
OCF(TTM)-8.75
OCFYN/A
SpS3.08
BVpS1.74
TBVpS1.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.58%
ROE -784.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.84%
ROA(5y)-56.7%
ROE(3y)-70.22%
ROE(5y)-72.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.32%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.4
Quick Ratio 7.4
Altman-Z -7.61
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)39.81%
Cap/Depr(5y)46.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.37%
EPS Next Y56.81%
EPS Next 2Y31.36%
EPS Next 3Y19.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-20%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.77%
OCF growth 3YN/A
OCF growth 5YN/A